What is the Roche Accu-Chek CGM?

Find out about Roche's Accu-Chek CGM. We outline the key features and give you a comparison with similar medtech so that you can evaluate if this is suitable for your needs.

Courtesy of Roche.

🩺 Overview

The Accu-Chek® SmartGuide CGM is Roche's latest innovation in continuous glucose monitoring, designed to provide real-time glucose readings and predictive insights for adults with type 1 and type 2 diabetes on flexible insulin therapy.The system integrates a wearable sensor with two dedicated mobile applications to deliver comprehensive glucose data and forecasts.

📲 Key features

• Sensor Design: The sensor comes with an all-in-one disposable applicator for straightforward application.

  
  

• Wear Duration: Each sensor is designed for a 14-day wear period.

  
  

• Water Resistance: The sensor has an IP28 rating, indicating protection against temporary immersion in water at a depth of 1 meter for up to 60 minutes.

  
  

• Warm-Up Time: After applying a new sensor, it requires a 1-hour warm-up period during which no glucose values are displayed in the app. After this period, the sensor enters Trend Mode and begins transmitting glucose readings every five minutes.

• Real-Time Monitoring: The sensor transmits glucose readings every five minutes via Bluetooth to the Accu-Chek® SmartGuide app.

  
  

• Predictive Insights: The Accu-Chek® SmartGuide Predict app utilizes AI-trained algorithms to forecast glucose trends over the next 30 minutes to two hours and assess the risk of nocturnal hypoglycemia.

  
  

• Data Logging: Users can log insulin doses, carbohydrate intake, and other relevant information within the app.

  
  

• Customizable Alerts: The system offers customizable glucose alarms to help users take corrective actions promptly.

  
  

• Data Sharing: Glucose data can be shared with healthcare professionals through the Accu-Chek® Care platform, facilitating collaborative diabetes management.

💬 Customer insights

• Accuracy: Clinical studies have demonstrated a mean absolute relative difference (MARD) of 9.2%, with 99.8% of glucose values falling within zones A and B on the Parkes Error Grid, indicating high accuracy.

  
  

• User Satisfaction: In a study involving 48 participants, 83% reported liking or very much liking the Accu-Chek® SmartGuide CGM device, and about 80% appreciated the app design.

  
  

🔄 CGM Comparison

Feature	Accu-Chek	FreeStyle Libre 2 Plus	Dexcom G7
Sensor shape & size		Circular, 35mm x 5mm	Irregular shape, 60% smaller than G6
Sensor wear duration		15 days	10 days
Warm-up time		1 hour	30 minutes
Application		Two-part application	One-piece applicator
Optional calibration		No	Yes
Data transmission
Integrations	app	LibreLink & LibreView apps	Dexcom App + Clarity, Apple Watch integration
Alerts	Yes, customisable	Yes, optional	Yes with predictive high & low alarms
Water resistance	IP28 (up to 1 metre for up to 60 minutes)	IP67	IP68
Approved wear sites (UK)	Abdomen (adults 18+) - UK to be confirmed when available
MARD	9.2%	8.2%	9.2%
Reader availability
Direct to Smartwatch	No	No	Yes
Approved age (UK)	2+ years
Grace period	No	No	Yes, 12 hours

For complete details on each option please refer to manuafacturer's website and documentation.

Current Availability

The Accu-Chek® SmartGuide CGM is currently available or being marketed in the following countries:

• Germany

• Switzerland

• Netherlands

These markets were prioritized following the CE Mark approval in July 2024, with launches commencing in the subsequent months.

Future Expansion

Roche is actively pursuing regulatory approvals and market expansion for the Accu-Chek® SmartGuide CGM. The company is in discussions with the US Food and Drug Administration (FDA) regarding potential entry into the U.S. market. Additionally, Roche is considering a pediatric indication for the device, although specific timelines for these developments have not been disclosed.

Manufacturer overview

Company Name: F. Hoffmann-La Roche Ltd

Website: www.roche.com

Founded: 1896

Headquarters: Basel, Switzerland

Global Presence: Operates in over 100 countries

Employees: Approximately 100,000 worldwide

Global Reach and Achievements

Roche is a global leader in biotechnology and in-vitro diagnostics, committed to advancing science to improve people's lives. The company has been recognized for its sustainability efforts, being named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for fifteen consecutive years.

Technological Innovation

Roche's Accu-Chek® SmartGuide CGM system represents a significant advancement in diabetes management, integrating AI-driven predictive algorithms to provide users with foresight into their glucose trends. This proactive approach aims to empower users to make informed decisions and reduce the risk of hypoglycemic events.

Notes

• Always consult a healthcare professional to determine the best CGM for your personal needs.

• Wear site approval may vary by country and regulatory status. Always follow the manufacturer's instructions.